ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
33,700
-100 (-0.30%)
Mar 28, 2025, 3:30 PM KST
34.26%
Market Cap 1.64T
Revenue (ttm) 33.40B
Net Income (ttm) -55.53B
Shares Out 48.53M
EPS (ttm) -1,156.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 429,242
Average Volume 890,843
Open 34,700
Previous Close 33,800
Day's Range 33,150 - 35,200
52-Week Range 21,200 - 47,250
Beta 0.91
RSI 37.28
Earnings Date Mar 12, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.